Background & Aims Tools for stratification of relapse risk of Crohn's disease (CD) after anti–
tumor necrosis factor (TNF) therapy cessation are needed. We aimed to validate a …

Background We sought to report the effectiveness of infliximab and adalimumab over the
first 3 years of treatment and to define the factors that predict anti-TNF treatment failure and …

BACKGROUND Traditional methods of developing predictive models in inflammatory bowel
diseases (IBD) rely on using statistical regression approaches to deriving clinical scores …

Background Anti-tumor necrosis factor (TNF) therapy is an important treatment option for
management of active Crohn's disease (CD) and is labeled for use after failure of …

Objective To determine the potential predictors of loss of response (LOR) to infliximab (IFX)
maintenance therapy for adult patients with Crohn's disease (CD). Methods We searched for …

OBJECTIVE: Infliximab is an effective treatment for refractory or fistulizing Crohn's disease
(CD). However, about 30% of patients do not respond to infliximab for unknown reasons …

BACKGROUND The individual performances and the complementarity of Crohn's disease
(CD) activity index (CDAI), C-reactive protein (CRP) and faecal calprotectin (Fcal) to monitor …

OBJECTIVES: To perform a meta-analysis of the risk of relapse after discontinuation of anti-
tumor necrosis factor (anti-TNF) therapy in patients with Crohn's disease (CD) and ulcerative …

Background The long‐term efficacy of infliximab in patients with Crohn's disease is
suboptimal. Aim To study prognostic factors for real‐life long‐term effcacy of infliximab in …

Background Anti-TNF drugs are effective treatments for the management of Crohn's disease
but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors …